Related Experiment Video

Updated: Aug 14, 2026

Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

[Drug therapy of inflammatory arthritis in children]

A M Prieur1

  • 1Unité de rhumatologie pédiatrique, Hôpital Necker-Enfants Malades, Paris.

La Revue Du Praticien
|December 1, 1994
PubMed

Insights

Drug treatments for juvenile chronic arthritis vary by subtype and age. Aspirin is a common pediatric NSAID, while other NSAIDs and specific antirheumatic drugs suit different subtypes, with methotrexate showing promise.

Area of Science:

  • Pediatric Rheumatology
  • Pharmacology

Context:

  • Juvenile chronic arthritis (JCA) treatment is complex, with drug efficacy and tolerance influenced by disease subtype and patient age.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, are frequently used in pediatric JCA due to dosage flexibility in low-weight children.
  • Many NSAIDs are restricted in young patients in France, despite potential benefits.

Purpose:

  • To review current drug treatment strategies for various subtypes of juvenile chronic arthritis.
  • To highlight the varying efficacy and side effect profiles of different drug classes across JCA subtypes.
  • To identify areas for further research in optimizing pharmacotherapy for pediatric rheumatic diseases.

Summary:

  • Drug selection for JCA depends on subtype: NSAIDs for joint pain, slow-acting antirheumatic drugs for polyarticular JCA, and local therapy for oligoarticular JCA.
  • Methotrexate is a viable option for JCA, though efficacy differs by subtype.
  • Severe side effects are noted with gold and sulphasalazine in systemic JCA, and oral corticosteroids are reserved for NSAID-resistant cases or intolerance.

Impact:

  • Provides a comprehensive overview of pharmacologic management for pediatric rheumatologists and healthcare providers.
  • Informs clinical decision-making regarding drug selection and monitoring in juvenile chronic arthritis.
  • Underscores the need for further controlled studies to evaluate the efficacy of immunosuppressive agents in JCA.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...